Faron Pharmaceuticals Oy (LON:FARN – Get Free Report) shares passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 186.42 ($2.35) and traded as low as GBX 165 ($2.08). Faron Pharmaceuticals Oy shares last traded at GBX 165 ($2.08), with a volume of 2,665 shares traded.
Faron Pharmaceuticals Oy Stock Performance
The company has a quick ratio of 1.09, a current ratio of 1.45 and a debt-to-equity ratio of 922.55. The stock has a market cap of £221.52 million, a P/E ratio of -4.41 and a beta of 0.36. The stock has a fifty day simple moving average of GBX 182.17 and a 200-day simple moving average of GBX 186.42.
Faron Pharmaceuticals Oy Company Profile
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Featured Articles
- Five stocks we like better than Faron Pharmaceuticals Oy
- EV Stocks and How to Profit from Them
- NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide Investment
- What is a Secondary Public Offering? What Investors Need to Know
- Up 50% in January, Twilio’s Pullback Is the Time to Buy
- What is the Australian Securities Exchange (ASX)
- Watch These 3 Stocks—High Short Interest and Big Upside Potential
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
